The pharmaceutical, biologics, and medical device industries need to prepare for changes as the new president and Congress settle into the nation’s capital. Our expert panel of D.C. insiders from King & Spalding will discuss the aftermath of the bitter election campaign, the leaders or likely future leader of relevant government committees and agencies, and the legislative and regulatory challenges pharmaceutical, biologics and device manufacturers may face in 2025.  

For questions, contact Christine Lieber.